Roche Enters Additional Sectors with Acquisition of Ariosa
By LabMedica International staff writers Posted on 09 Dec 2014 |
Healthcare biotech leader Roche (Basel, Switzerland) has announced its acquisition of privately held Ariosa Diagnostics, Inc. (San Jose, CA, USA), a leading molecular diagnostics testing service provider of a highly targeted and accurate noninvasive prenatal testing (NIPT) service through their CLIA laboratory using cell-free DNA (cfDNA) technology.
Ariosa’s proprietary “Harmony Prenatal Test” is a blood test performed as early as 10 weeks into pregnancy. By evaluating fetal cfDNA found in maternal blood, the test is designed to assess the risk of Down syndrome and other genetic abnormalities. Specifically, the test assesses the risk of trisomies 13, 18, and 21, which are indicative of an extra chromosome in the fetus that can lead to severe genetic conditions. Prenatal screening for Down syndrome has become common practice in many countries; however, conventional screening tests return false-positive results up to 5% of the time, much higher than the 0.1% false-positives of the Harmony Prenatal Test. The test has been validated to CLIA requirements by a robust clinical data set and supported by clinical studies in more than 22,000 women of all ages and risk categories. Data have not yet been submitted to or evaluated by regulatory agencies and the test is currently not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
With the acquisition, Roche enters both the NIPT and cfDNA testing services sectors. “The acquisition of Ariosa is another example of Roche’s commitment to advanced molecular diagnostics,” said Roland Diggelmann, COO Roche Diagnostics Division, “Circulating cfDNA has the promise of providing early diagnostic information through a simple blood test in many important segments including pregnancy, cancer, and transplantation, aligning with our strategy in personalized healthcare and commitment to setting new standards of care.”
“We are thrilled to join forces with Roche to continue in our commitment to bringing forward high quality and affordable genetic testing that positively impacts the medical care of patients around the world,” said Ken Song MD, CEO of Ariosa.
Related Links:
Roche
Ariosa Diagnostics
Ariosa’s proprietary “Harmony Prenatal Test” is a blood test performed as early as 10 weeks into pregnancy. By evaluating fetal cfDNA found in maternal blood, the test is designed to assess the risk of Down syndrome and other genetic abnormalities. Specifically, the test assesses the risk of trisomies 13, 18, and 21, which are indicative of an extra chromosome in the fetus that can lead to severe genetic conditions. Prenatal screening for Down syndrome has become common practice in many countries; however, conventional screening tests return false-positive results up to 5% of the time, much higher than the 0.1% false-positives of the Harmony Prenatal Test. The test has been validated to CLIA requirements by a robust clinical data set and supported by clinical studies in more than 22,000 women of all ages and risk categories. Data have not yet been submitted to or evaluated by regulatory agencies and the test is currently not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
With the acquisition, Roche enters both the NIPT and cfDNA testing services sectors. “The acquisition of Ariosa is another example of Roche’s commitment to advanced molecular diagnostics,” said Roland Diggelmann, COO Roche Diagnostics Division, “Circulating cfDNA has the promise of providing early diagnostic information through a simple blood test in many important segments including pregnancy, cancer, and transplantation, aligning with our strategy in personalized healthcare and commitment to setting new standards of care.”
“We are thrilled to join forces with Roche to continue in our commitment to bringing forward high quality and affordable genetic testing that positively impacts the medical care of patients around the world,” said Ken Song MD, CEO of Ariosa.
Related Links:
Roche
Ariosa Diagnostics
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance